Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild type primary glioblastoma
We stratified 69 primary IDH-wt GBM patients into TMZ-resistant (n = 29) and sensitive (n = 40) groups, using TMZ screening of the corresponding patient-derived glioma stem-like cells (GSCs). Genomic and transcriptomic features were then examined to identify TMZ-associated molecular alterations. Subsequently, we developed a machine learning (ML) model to predict TMZ response from combined signatures. Moreover, TMZ response in multisector samples (52 tumor sectors from 18 cases) was evaluated to validate findings and investigate the impact of intra-tumoral heterogeneity on TMZ efficacy.
- 113 samples
- DAC: EGAC00001003085
- Technology: Illumina HiSeq 2500
Samsung Medical Center (SMC) - Institute for Refractory Cancer (IRCR) Data Access Policy
SMC-IRCR data access policy generally respects the guidelines of NIH genomic data sharing policy (http://gds.nih.gov/PDF/NIH_GDS_Policy.pdf), but can be overridden by consensual decision of DAC in exceptional cases.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |